***** seminarMLから情報転載 *****


Date and Time: May 30&s_comma; 2011 16:00 - 17:00
Venue : 1st Building&s_comma; 2F Conference Room&s_comma; Inst.Med.Sci&s_comma; Univ. Tokyo 
(東京大学医科学研究所、本館2階会議室)
Speaker: Dr. Peter Kiener
Position : President and CEO
Affiliation:Zyngenia&s_comma; Inc
(Country) USA
Seminar Title: “Zybodies: Building mAb-based biotherapeutics that are
able to interact concomitantly with multiple targets”
(Language) English

Summary:Kiener 博士はオクスフォード大学で生化学で学位を取られた後、米国の大学、
製薬企業にて一貫して免疫関係の医薬品開発を行ってこられました。2005年よりMedImmune
社にて新規抗体医薬品の開発に取り組み、研究開発副社長として、AstraZenecaとの合併を
指導し、同社を世界トップレベルの抗体開発企業に育てあげられました。一昨年よりZyngenia
社を創立し、次世代の新規抗体医薬品開発の最前線で活躍しておられます

Short summary of the talk:
mAbs just target single antigens whereas diseases are often driven by several
mechanisms that cannot be addressed through a single specificity.
One solution is single molecule therapeutics that have all the desired properties
of a mAb but are able to simultaneously target several mediators or pathways of
disease. We call these Zybodies. These molecules create novel activities that cannot be
achieved with a single&s_comma; or even mixtures of mAbs&s_comma; and thus provide for better
disease intervention. Furthermore&s_comma; these also are made with the cost and development
paradigm of a single agent.

Host: Sumiko Watanabe (Division of Molecular and Developmental Biology)&s_comma;

Hiroshi Kiyono (Division of Mucosal Immunology)




seminarMLに関する情報は「バイオ関係者、皆のホームページ」特選MailingList_Forum欄でアクセスできる。